A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Several pharmaceutical companies are developing novel weight-loss drugs that focus not just on reducing fat but also on ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

June 2 (Reuters) - Regeneron (REGN.O), opens new ... the highest rate among all groups tested in the study. "Incremental improved weight loss from double and triple therapy are promising," said ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

In the study involving 599 patients ... aiming for a share of the $150 billion weight-loss market. In addition, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed plans to license an ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.